NCT00582608|TerminatedResults
Study Stopped
Lack of accrual
Loading search results
Sponsor study identifier
interventional
12
1 country
1
Study Start
October 2001
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
May 2009
Actual (reported)Study Completion
May 2009
Actual (reported)The purpose of this study is to find out whether the monoclonal antibody 8H9 is useful in finding tumors in your body. Antibodies are protein found naturally in blood. They can fasten themselves to bacteria and viruses. They can stimulate white cells and blood proteins to kill tumors. The antibody 8H9 was made from mouse white cells. The white cells that secrete this antibody have been made to live for ever. They manufacture large amounts of 8H9 for patient use. Although other monoclonal antibodies have been safely tested in people, the antibody 8H9 has never been given to a human patient.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 2009
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 2001
Date type not reportedThis date has not been verified as actual or estimated.
December 21, 2007
Actual (reported)December 28, 2007
Actual (reported)May 2009
Actual (reported)May 2009
Actual (reported)March 1, 2017
Actual (reported)Safety and Toxicity is Measured by the Total Number of Participants Affected
Safety and toxicity is measured by the total number of participants affected. Please see the adverse event table for the specifics for this protocol.
2 years
This is an open-label single arm study of 131 I-8H9. injected intravenously at 10mCi/1.73m\^2 dose \[intended specific activity of '20mCi/mg protein\] preceded by administration of 50mg/1.73m2 of unlabeled -8H9.
This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m\^2 dose \[intended specific activity of \~20 mCi/mg protein\]
administration of 50mg/1.73m\^2 of unlabeled 8H9.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Technical problems led to unreliable and uninterpretable data. Therefore, there is no data to report under Outcome Measures. Due to lack of patients accrual.
Shakeel Modak, MD
Memorial Sloan Kettering Cancer Center
12 participants (actual enrollment reported by the registry).
First Submitted
December 21, 2007
First Posted
December 28, 2007
Study Start
October 2001
Date type not reportedThis date has not been verified as actual or estimated.
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
Contact the study team to confirm eligibility.
Primary Completion
May 2009
Actual (reported)Study Completion
May 2009
Actual (reported)Last Updated
March 1, 2017
Results First Posted
March 1, 2017
Record last verified: 2017-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: